VPVladislav Pajović

Vladislav Pajović

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Vladislav Pajović has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Anesthetic and Sedative Effects on Echocardiographic Parameters in Rat Models of Cardiomyopathy: A Critical Review

    by Vladislav Pajović, Marija Kosić, Mirjana Jovanović, Nina Japundžić-Žigon

    Cardiomyopathies represent a heterogeneous group of diseases that lead to functional and structural impairment of the myocardium, frequently culminating in heart failure. Due to ethical and technical constraints inherent to human studies, rat models have become indispensable in experimental cardiology. Transthoracic echocardiography represents one of the most commonly used methods for assessing cardiac structure and function in experimental rat models of cardiomyopathy, due to its accessibility, non-invasiveness, ease of use, safety and cost-effectiveness. Almost all echocardiographic examinations in rats require a certain level of pharmacological sedation or general anesthesia to immobilize the animal and reduce motion-induced artifacts. A review of the literature reveals that only a few anesthetics are used in experimental practice. By far the two most prevalent choices are isoflurane and the ketamine-xylazine combination. Less frequently used are pentobarbital, the tiletamine-zolazepam combination, sevoflurane, and acepromazine. However, the interpretation of echocardiographic findings in experimental animals can be significantly biased by the effects of anesthesia primarily on the autonomic nervous system and cardiac contractility. Therefore the choice of anesthetic or sedative protocol represents an important, yet insufficiently standardized, methodological variable in the echocardiographic assessment of rat models of cardiomyopathy. Here we discuss the bias introduced by the use of sedatives/anesthetics when performing echocardiography in different rat models of experimental cardiomyopathy.

  • Open Access

    Drug Repositioning in Doxorubicin-Induced Cardiotoxicity Protection

    by Marija Kosić, Vladislav Pajović, Mirjana Jovanović, Nina Japundžić-Žigon

    Doxorubicin (DOX) is an effective drug for the treatment of solid tumors and hematological malignancies in both children and adults. The most serious side effect is doxorubicin-induced cardiotoxicity (DIC), which can lead to cardiomyopathy and irreversible and highly fatal cardiac decompensation. The precise mechanisms underlying DIC are not fully understood, and currently, no fully effective preventive or therapeutic strategies exist. Drug repositioning has emerged as a promising approach to mitigate DIC, leveraging existing safety profiles while potentially reducing the time and cost of clinical translation. In this review, we summarize current evidence on drug repurposing for DIC, with a particular focus on the antidepressant paroxetine, which shows potential cardioprotective effects beyond its established role as a selective serotonin reuptake inhibitor (SSRI).


  • Role of vasopressin in adaptation to pregnancy in chronic hypertension

    by Mirjana Jovanovic, Bojana Stevanovic, Vladislav Pajovic, Tatjana Tasic, Maja Lozic, Ljiljana Djukic, Marija Kosic, David Murphy, Nina Japundzic Zigon, University of Belgrade

    Cardiovascular system (CVS) adaptation during pregnancy involves numerous hemodynamic changes and remodeling of peripheral and central regulatory mechanisms. A decrease in blood pressure (BP) during pregnancy activates the baroreflex, leading to an increase in sympathetic tone and the synthesis and secretion of vasopressin (VP). It is well-established that VP plays a critical role in the adaptation to normotensive pregnancy, as well as in the development of primary hypertension. However, the effects of VP on neuroendocrine and autonomic adaptation of the CVS in the context of chronic hypertension during pregnancy remain insufficiently studied. This study was conducted on normotensive Wistar (WR) and spontaneously hypertensive rats (SHR) implanted with radiotelemetry devices for continuous hemodynamic measurements. BP and heart rate (HR) variability were assessed through spectral analysis, while baroreflex sensitivity (BRS) was measured using the sequence method. Plasma VP concentration was measured by ELISA, and gene expression of VP, V1aR, and V1bR was analyzed via RT-qPCR. The results indicate that non-pregnant SHR females exhibit higher gene expression of VP, V1aR, and V1bR in the paraventricular nucleus (PVN) and supraoptic nucleus (SON) compared to WR females in diestrus. Pregnant SHR females show reduced VP expression in the SON, lower plasma VP concentrations, and normalized BP during late pregnancy, but also exhibit signs of increased sympathetic cardiac stimulation (elevated HR and LF-HR), as well as activation of vagal mechanisms (increased BRS and HF-HR). In WR females, late pregnancy induces increased gene expression of VP in the PVN and SON, while changes in plasma VP levels and BP are less pronounced, as are alterations in autonomic control. These findings indicate differences in adaptation between WR and SHR females.

  • Open Access

    Pharmacogenetics of cardiovascular drugs

    by Vladislav Pajović, Nina Žigon

    Individual variations in the patient's response to the administered drugs are a frequent and important clinical problem in medicine and pharmacology. It is especially important to consider these issues when counting cardiovascular disease (CVD) treatment, since CVD is characterized by high incidence in the population, making cardiovascular drugs the most prescribed medication. Currently used medical therapies are adapted to best fit the needs of a wide population of patients who can benefit from them, despite the fact that a certain number of individuals will suffer from inadequate therapeutic effects or even intoxication. By examining the genetic basis that causes individual variations in the response to drugs, pharmacogenetics enables the personalization of drug therapy, with the aim to identify patients who are exposed to an increased risk of serious drug side effects and those missing the maximum drug effectiveness. Polymorphisms of genes that encode protein units of enzymes involved in the drug metabolism, mainly cytochrome P450 enzymes, receptors and drug transporters, affect both pharmacokinetics and pharmacodynamics of drugs often prescribed for CVD, such as beta-blockers, ACE inhibitors, warfarin, clopidogrel, and statins. This approach in cardiological practice would enable adjusting the therapy for patients based on gene polymorphisms, by changing the dose of the existing drugs or using another drug of choice. Although including pharmacogenetics in daily clinical practice would bring along large diagnostic costs, as well as potential legal and ethical dilemmas, a substantial number of patients, overall society, and the health system, in general, could benefit from enhanced therapeutic effects as well as decreased side effects of the applied therapy.